These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19343141)

  • 41. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
    Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
    Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systemic therapy for esophagogastric cancer: targeted therapies.
    Lyons TG; Ku GY
    Chin Clin Oncol; 2017 Oct; 6(5):48. PubMed ID: 29129088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
    Wang JP; Wu CY; Yeh YC; Shyr YM; Wu YY; Kuo CY; Hung YP; Chen MH; Lee WP; Luo JC; Chao Y; Li CP
    Oncotarget; 2015 Jul; 6(20):18162-73. PubMed ID: 26046796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
    Byers LA; Heymach JV
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S79-85. PubMed ID: 17382029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of advanced pancreatic cancer.
    Ducreux M; Boige V; Malka D
    Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
    Bellmunt J; Hussain M; Dinney CP
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
    Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
    Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pancreatic cancer: from molecular signature to target therapy.
    Longo R; Cacciamani F; Naso G; Gasparini G
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):197-211. PubMed ID: 18436450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genomics and pharmacogenomics of pancreatic adenocarcinoma.
    Lowery MA; O'Reilly EM
    Pharmacogenomics J; 2012 Feb; 12(1):1-9. PubMed ID: 22186617
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical experience with erlotinib in non-small-cell lung cancer.
    Felip E; Rosell R
    Drugs Today (Barc); 2006 Mar; 42(3):147-56. PubMed ID: 16628257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New molecular targeted therapies integrated with radiation therapy in lung cancer.
    Provencio M; Sánchez A; Garrido P; Valcárcel F
    Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Her signaling in pancreatic cancer.
    Burtness B
    Expert Opin Biol Ther; 2007 Jun; 7(6):823-9. PubMed ID: 17555368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
    Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
    Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
    da Cunha Santos G; Dhani N; Tu D; Chin K; Ludkovski O; Kamel-Reid S; Squire J; Parulekar W; Moore MJ; Tsao MS
    Cancer; 2010 Dec; 116(24):5599-607. PubMed ID: 20824720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.